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Negative MR40 chronic myeloid leukaemia and its possible
implications for treatment-free remission
ABL1 tyrosine kinase inhibitors (TKI) have dramatically
improved the outcome for chronic myeloid leukaemia
(CML) patients, resulting in a life expectancy that approaches
that of the general population. Nevertheless, lifelong TKI
therapy may have consequences, including chronic adverse
events that can substantially impact patients’ quality of life,
adherence to therapy and treatment success. Recently, several
clinical discontinuation trials have demonstrated that 40–
60% of chronic phase CML patients (CP-CML) who have
achieved a stable deep molecular response (DMR) can stop
therapy without relapsing (Breccia & Foa, 2018). Laboratory
recommendations for scoring DMR were previously defined
as MR40 [either detectable disease ⩽001% BCR-ABLIS
(MR40 positive) or undetectable disease in cDNA with
10 000–31 999 ABL1 transcripts or 24 000–76 999 GUSB
transcripts (MR40 negative)], MR45 [either detectable disease
⩽00032% BCR-ABLIS (MR45 positive) or undetectable dis-
ease in cDNA with 32 000–99 999 ABL1 transcripts or
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77 000–239 999 GUSB transcripts (MR45 negative)], and
MR50 [either detectable disease ⩽0001% BCR-ABLIS (MR50
positive) or undetectable disease in cDNA with ⩾100 000
ABL1 transcripts or ⩾240 000 GUSB transcripts (MR50 nega-
tive)] (Cross et al, 2015).
Most trials enrolled only patients with a molecular response
of 45 or deeper, sustained for at least two years (Breccia &
Foa, 2018). Recently, the EURO-SKI study evaluated the feasi-
bility of treatment interruption in patients in confirmed
MR40 for at least 1 year (Saussele et al, 2018). Treatment
duration and molecular response duration emerged as vari-
ables that had the largest effect on treatment cessation success
(Saussele et al, 2018). A sub-analysis of the EURO-SKI study
detected no differences in molecular relapse-free survival
(RFS) between patients in MR40 who never achieved a MR45
(61%) compared to detectable MR45 (51%) or undetectable
MR45 (62%) (Pfirmann et al, 2016). A subsequent analysis
reported no differences in molecular relapse after stopping
therapy in MR40, whether residual disease was detected or not
(Pfirmann et al, 2017). These observations seem to suggest
that there is no difference between MR40 and MR45 in terms
of success of treatment-free remission (TFR). Despite these
results, there is no consensus as to whether or not the depth
of the molecular response is a prognostic factor for TFR,
which is reflected in the discrepancy between the various
guidelines and opinions of experts in the field regarding the
optimal molecular response required, MR40 or MR45, for a
TFR attempt (Hughes & Ross, 2016; Mahon, 2017; Hochhaus
et al, 2018; National Comprehensive Cancer Network, 2018).
In addition, despite the efforts made in recent years to stan-
dardize the quantification and reporting of BCR-ABL1 levels
in CML patients (Cross et al, 2015), the degree of sensitivity
variation of the different methodologies among different labo-
ratories remains unknown.
We hypothesized that a discrepancy in the classification of
the level of molecular response between laboratories involved
in clinical trials could introduce a bias in the evaluation of
the prognostic impact of TFR. In an attempt to clarify this
issue, we evaluated a cohort of 1087 CML patients treated
with TKIs in Portugal monitored by real-time quantitative
reverse transcription polymerase chain reaction (qRT-PCR).
The patients were monitored in two European Treatment
and Outcome Study (EUTOS)-certificated laboratories in
Porto and Lisbon and in three additional centres that have a
validated conversion factor. All laboratories reported the
results in the international scale according to Cross et al
(2015). ABL1 and GUSB reference genes were used for nor-
malization and classification of depth of molecular response
in BCR-ABL1 negative cases in 4 and 1 laboratories, respec-
tively. Only patients with typical BCR-ABL1 transcripts
(e13a2 and e14a2) were included. At the last evaluation, 610
patients (56%) were in DMR: 169 (28%) in MR40, 211
(35%) in MR45 and 230 (38%) in MR50 (Fig 1A). Interest-
ingly, none of the 169 patients classified as MR40 had unde-
tectable disease. In addition, as expected, the frequency of
undetectable disease-negative cases was higher in the MR45
(29%, 61/211) and MR50 (65%, 149/230) groups (Fig 1A), as
the threshold of sensitivity of the current qRT-PCR method-
ology was reached. We compared our results to those of the
EURO-SKI trial, which used the molecular monitoring data
of patients from 61 centres in 11 European countries (Saus-
sele et al, 2018). As no detailed stratification of CML patients
by molecular response was published in the last analysis of
the EURO-SKI trial (Saussele et al, 2018), we used the data
of the first interim analysis, which included 200 patients
(Saussele et al, 2014). Of these, 196 were evaluable for molec-
ular response: 68 (35%) were in MR40, 85 (43%) in MR45
and 43 (22%) in MR50 (Fig 1B). The frequency of MR40
with undetectable disease was 72% (49/68), decreasing to
56% (48/85) and 58% (25/43) in the MR45 and MR50
groups, respectively. The unexpected distribution of the
EUROSKI data could potentially be caused by a small num-
ber of laboratories with poor performing assays or poorly
calibrated assays that overestimate the number of reference
gene transcripts. Supporting this hypothesis is the absence of
detectable disease in our MR40 patients using optimized
qRT-PCR methodologies not available at the time in most
laboratories, before MR45 standardization within the EUTOS
project. However, this does not explain the observed lower
Fig 1. Stratification of chronic myeloid leukaemia patients in deep
molecular response by level of molecular response. (A) Deep molecu-
lar response data from 610 Portuguese chronic myeloid leukaemia
patients (B) Deep molecular response data from 196 chronic myeloid
leukaemia patients included in the EURO-SKI trial (Saussele et al,
2014).
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proportion of undetectable disease observed in the MR45
and MR50 groups when compared with the MR40 group in
the EURO-SKI trial. In addition, the higher proportion of
MR50 with detectable disease observed in the EURO-SKI
when compared with our series is also difficult to explain.
Nevertheless, if this data sampling of the EURO-SKI trial is
representative of the final series, there may be a bias in
patient stratification by molecular response, making it
impractical to attempt any association between molecular
response depth and TFR success, at least for patients with
undetectable disease. Thus, more studies are needed in order
to clarify whether TFR can be accomplished successfully in
CML patients with responses less than MR45. Moreover, our
data also suggests that: (i) the molecular response criteria
used to select patients for TFR trials should be modified, so
that all patients with MR40 and undetectable disease should
be excluded and (ii) the results of the distribution of patients
by molecular response level should be published with the
TFR data. Finally, considering the limitations of qRT-PCR,
the implementation of even more sensitive and accurate
methods, such as digital PCR, may provide more robust esti-
mates of molecular response levels, improving the selection
of patients for a TFR trial.
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A novel missense mutation in a leucine-rich repeat of GPIba in
a Bernard-Soulier variant reduces shear-dependent adherence
on von Willebrand factor
Bernard-Soulier syndrome (BSS) is a rare inherited haemor-
rhagic disorder in which thrombocytopenia is associated
with giant platelets and defective adherence to the vessel
wall. In almost every case the underlying defect is the absent
expression of the glycoprotein Ib-IX-V complex (GPIb-IX-
V), the von Willebrand factor (VWF) receptor. Very rarely,
subnormal (20–50%) levels of a dysfunctional GPIb-IX-V
complex in BSS variants have also been described (Ware
et al, 1993; Clemetson et al, 1994; Ulsemer et al, 2000).
Mutations in the GP1BA, GP1BB and GP9 genes, but not
GP5 give rise to BSS. A recent survey by a BSS consortium
reported 112 different mutations affecting these three genes
(Savoia et al, 2014). Two cases with missense substitutions
in GP1BA have been reported in the Bolzano (p.Ala172Val)
and Nancy I (p.Leu195del) BSS variants, both within the
Leu-rich repeat (LRR) region of GPIba. We report the case
of a 5-year-old boy with a bleeding tendency, who was ini-
tially referred for refractory chronic thrombocytopenia (pla-
telet count: 15–50 9 109/l). Patient details and materials and
methods are given in Appendix S1. Blood smears showed
the presence of giant platelets and bone marrow smears
showed abnormal megakaryocytes with large vacuoles (Fig
1A). Transmission electron microscopy confirmed the
increased platelet size and highlighted the abnormal presence
of large vacuoles and membrane complexes (Fig 1B). Platelet
aggregation studies showed a complete and isolated loss of
ristocetin- and botrocetin-induced agglutination (Fig 1C, D).
However, the patient’s platelets were able to adhere on a
VWF-coated surface in the presence of botrocetin (Fig 1E),
suggesting some residual function. Surface expression of
GPIbb, GPIX and GPV was 50–70% of normal whereas
expression of GPIba varied from 20% to 30% of control for
a series of monoclonal antibodies (mAbs) against the Leu-
rich and macroglycopeptide domains but was nearly unde-
tectable for mAb 6D1 against LRR-5, pointing to a defect in
this domain (Table S1). Sequencing of GP1BA, GP1BB and
GP9 confirmed the diagnosis, identifying a homozygous
c.416T>C substitution in GP1BA in the LRR-5 (p.Leu139-
Pro) in a highly conserved region of the gene (Fig 1F, G),
and probably explaining the lack of recognition by mAb
6D1. Both consanguineous parents were heterozygous for the
same mutation whereas a brother and a sister were homozy-
gous for the normal sequence (Fig 1F). 3-D modelling shows
that Leu139 is located in the convex loop of the LRR-5 of
the N-terminal ligand-binding domain (LBD) of GPIba,
tightly packed with other hydrophobic residues and its side
chain helping to make the hydrophobic core of the domain
(Figure S1A). Thus, the p.Leu139Pro mutation is expected to
disrupt the structural integrity of the LBD or severely desta-
bilize it. However, being located in the middle of the LRR
domain, it may preserve the conformation of the C-terminal,
botrocetin-binding site. Reproduction of the mutated com-
plex in Chinese hamster ovary (CHO) cells confirmed the
pathogenicity of the mutation. The p.Leu139Pro change in
GPIba introduced into a CHO cell stably expressing GPIbb-
IX (CHOaL139PbIX) resulted in normal expression of GPIbb
and GPIX but only 48% of control for GPIba (Figure S2A).
Decreased but preserved VWF binding (38% of control) and
slightly decreased adherence to immobilized VWF were
observed in CHOaL139PbIX in the presence of botrocetin
(Fig 2A, B) compared to control cells. On the other hand,
there was a lack of ristocetin-induced agglutination (Fig 2C)
and a pronounced defect of cell adherence under flow condi-
tions in mutant compared to control cells. This was
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